However, the view that KC activation is a key mediator of MASLD pathology has been challenged by recent in vivo WD studies [253] and observations in obese patients [270], which do not support a traditional KC activation phenotype in MASLD. The gene discussed is CALCA; the disease is metabolic dysfunction-associated steatotic liver disease.